Skip Navigation


European Heart Journal Advance Access originally published online on January 9, 2006
European Heart Journal
2006 27(3):260-266; doi:10.1093/eurheartj/ehi721
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/3/260    most recent
ehi721v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mehilli, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehilli, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels

Julinda Mehilli1, Alban Dibra1, Adnan Kastrati1,*, Jürgen Pache1, Josef Dirschinger2, Albert Schömig1,2 for the Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators

1Deutsches Herzzentrum, Technische Universität, Lazarettstr. 36, 80636 Munich, Germany
2Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany

Received 12 December 2005; revised 24 December 2005; accepted 28 December 2005; online publish-ahead-of-print 9 January 2006.

* Corresponding author. Tel: +49 89 12184577; fax: +49 89 12184593. E-mail address: kastrati{at}dhm.mhn.de

Aims Sirolimus- and paclitaxel-eluting stents effectively reduce restenosis in small coronary vessels. The relative efficacy of these drug-eluting stents in this high-risk subset is not known.

Methods and results A total of 360 patients undergoing percutaneous coronary intervention for de novo lesions in native coronary vessels with a diameter of <2.80 mm received randomly paclitaxel-eluting stents (n=180) or sirolimus-eluting stents (n=180). The primary endpoint was in-stent late luminal loss. Secondary endpoints were angiographic restenosis and need of target lesion revascularization. The study intended to show that the paclitaxel-eluting stent is not inferior to the sirolimus-eluting stent with respect to the primary endpoint. The non-inferiority margin was set at 0.16 mm. Follow-up angiography was performed in 87% of the patients. In-stent late luminal loss in the paclitaxel-eluting stent group was 0.32 mm (upper 95% boundary, 0.42 mm), which was greater than that in the sirolimus-eluting stent group, failing to show the non-inferiority of the paclitaxel-eluting stent to the sirolimus-eluting stent (P>0.99). Angiographic restenosis was found in 19.0% of the lesions in the paclitaxel-eluting stent group and 11.4% of the lesions in the sirolimus-eluting stent group (P=0.047). Target lesion revascularization was performed in 14.7% of the lesions treated with paclitaxel-eluting stents and 6.6% of the lesions treated with sirolimus-eluting stents (P=0.008).

Conclusion The paclitaxel-eluting stent is associated with a greater late luminal loss and is less effective in reducing restenosis in small coronary vessels than the sirolimus-eluting stent.

Key Words: Coronary artery disease • Drug-eluting stents • Paclitaxel • Restenosis • Sirolimus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al.
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Eur. Heart J., March 2, 2008; 29(6): 718 - 725.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al.
Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
JAMA, January 30, 2008; 299(4): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Schomig, A. Dibra, S. Windecker, J. Mehilli, J. Suarez de Lezo, C. Kaiser, S.-J. Park, J.-J. Goy, J.-H. Lee, E. Di Lorenzo, et al.
A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1373 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. J. Kereiakes
The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1381 - 1385.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Togni, S. Eber, J. Widmer, M. Billinger, P. Wenaweser, S. Cook, R. Vogel, C. Seiler, F. R. Eberli, W. Maier, et al.
Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1123 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Colombo and A. Chieffo
Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Circulation, September 18, 2007; 116(12): 1424 - 1432.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Moreno, C. Fernandez, A. Sanchez-Recalde, G. Galeote, L. Calvo, F. Alfonso, R. Hernandez, R. Sanchez-Aquino, D. J. Angiolillo, S. Villarreal, et al.
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Eur. Heart J., July 1, 2007; 28(13): 1583 - 1591.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. S. Brilakis, S. Banerjee, and P. B. Berger
Perioperative Management of Patients With Coronary Stents
J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2145 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. H. Strauss
All Drug-Eluting Stents Are Equal, But Some Drug-Eluting Stents Are More Equal Than Others
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1310 - 1311.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Elezi, A. Dibra, J. Mehilli, J. Pache, R. Wessely, A. Schomig, and A. Kastrati
Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement: Results From a Large Cohort of Patients Treated With Sirolimus- or Paclitaxel-Eluting Stents
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1304 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. Saia, G. Piovaccari, A. Manari, A. Santarelli, A. Benassi, E. Aurier, P. Sangiorgio, F. Tarantino, G. Geraci, G. Vecchi, et al.
Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice: Results From a Large Multicenter Registry
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1312 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Rogers and E. R. Edelman
Pushing Drug-Eluting Stents Into Uncharted Territory: Simpler Than You Think--More Complex Than You Imagine
Circulation, May 16, 2006; 113(19): 2262 - 2265.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.